Exercise and Time of Day in Type 2 Diabetes

Summary

The overall purpose of the study is to test the effect of Noom on exercise and diet advice in adults with type 2 diabetes. The overarching hypothesis is that the use of Noom may promote better dietary adherence during an exercise program, thereby promoting greater weight loss and cardiometabolic health compared to lifestyle advice only. In particular, the investigators anticipate that changes in metabolic and vascular insulin sensitivity will correlate with glycemic control and blood pressure changes.

Eligibility

Inclusion Criteria:

* Male or female \>30 and \<70 years old.
* Has a body mass index \>28 and \<45 kg/m2.
* Previously diagnosed with T2DM.
* Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).

Exclusion Criteria:

* Morbidly obese patients (BMI \>46 kg/m2) and overweight/lean patients (BMI \<27 kg/m2)
* Evidence of type 1 diabetes and diabetics requiring insulin therapy
* Subjects who have not been weight stable (\>2 kg weight change in past 3 months)
* Subjects who have been recently active (\>30 min of moderate/high intensity exercise, 2 times/week).
* Subjects who are smokers or who have quit smoking \<1 years ago
* Subjects with abnormal estimated glomerular filtration rate (eGFR).
* Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects
* Hypertensive (\>160/100 mmHg)
* Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures or impact subject safety.
* Pregnant (as evidenced by positive urine pregnancy test) or nursing women
* Subjects with contraindications to participation in an exercise training program
* Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzphetamine, diethylpropion, phendimetrazine)
* Known hypersensitivity to perflutren (contained in Definity)

Conditions3

Locations3 sites

Browse More Trials